...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer >Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.
【24h】

Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.

机译：与其他5-羟色胺抑制剂（5-HT3R）相比，帕洛诺司琼（PAL）在预防中度或高度致呕性（MoHE）治疗的患者中预防化疗引起的恶心和呕吐（CINV）方面​​的功效：系统评价和荟萃分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: The objective of this work is to perform a systematic review and meta-analysis of all randomized controlled trials comparing a single intravenous dose of palonosetron (PAL) 0.25 mg with other 5-HT(3)R in patients receiving moderately or highly emetogenic (MoHE) chemotherapy. METHODS: Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoints were the incidence of acute and delayed nausea and vomiting. The side effects of each treatment were analyzed. A subgroup analysis was performed to evaluate the influence of the use of corticosteroids. The results are expressed as risk ratio (RR) and the correspondent 95% confidence interval (CI). RESULTS: Five studies were included, with 2057 patients. PAL was compared with ondansetron, granisetron, and dolasetron. Patients in PAL group had less nausea, both acute (RR = 0.86; CI 95% = 0.76 to 0.96; p = 0.007) and delayed (RR = 0.82; CI95% = 0.75 to 0.89; p < 0.00001). They also had less acute vomiting (RR = 0.76; CI 95% = 0.66 to 0.88; p = 0.0002) and delayed vomiting (RR = 0.76; CI95% = 0.68 to 0.85; p < 0.00001). There were no statistical differences in side effects like headache (RR = 0.84; CI 95% = 0.61 to 1.17; p = 0.30), dizziness (RR = 0.40; CI 95% = 0.13 to 1.27; p = 0.12), constipation (RR = 1.29; CI 95% = 0.77 to 2.17; p = 0.33) or diarrhea (RR = 0.67; CI 95% = 0.24 to 1.85; p = 0.44). Patients receiving PAL presented less nausea and vomiting regardless of the use of corticoids. We found no statistical heterogeneity in the global analysis. CONCLUSION: PAL was more effective than the other 5-HT(3)R in preventing acute and delayed CINV in patients receiving MoHE treatments, regardless of the use of concomitant corticosteroids.
机译：目的：这项工作的目的是对所有接受中度或高度呕吐的患者的单剂量静脉注射剂量的帕洛诺司琼（PAL）0.25 mg与其他5-HT（3）R进行比较，对所有随机对照试验进行系统的回顾和荟萃分析（MoHE）化学疗法。方法：搜索了多个数据库，包括MEDLINE，EMBASE，LILACS和CENTRAL。主要终点为急性和延迟的恶心和呕吐的发生率。分析了每种疗法的副作用。进行了亚组分析以评估使用皮质类固醇的影响。结果表示为风险比（RR）和相应的95％置信区间（CI）。结果：包括五项研究，2057例患者。将PAL与恩丹西酮，格拉司琼和多拉司琼进行了比较。 PAL组患者的恶心程度较低，既有急性（RR = 0.86; CI 95％= 0.76至0.96; p = 0.007），也有延迟的（RC = 0.82; CI95％= 0.75至0.89; p <0.00001）。他们的急性呕吐（RR = 0.76; CI 95％= 0.66至0.88; p = 0.0002）和延迟性呕吐（RR = 0.76; CI95％= 0.68至0.85; p <0.00001）较少。头痛（RR = 0.84; CI 95％= 0.61至1.17; p = 0.30），头晕（RR = 0.40; CI 95％= 0.13至1.27; p = 0.12），便秘（RR）等副作用没有统计学差异= 1.29; CI 95％= 0.77至2.17; p = 0.33）或腹泻（RR = 0.67; CI 95％= 0.24至1.85; p = 0.44）。无论使用皮质类固醇，接受PAL治疗的患者恶心和呕吐的发生率均较低。我们在全局分析中未发现统计异质性。结论：无论使用了同时使用的皮质类固醇，在接受MoHE治疗的患者中，PAL比其他5-HT（3）R预防急性和延迟CINV更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号